Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | GGPS1 | O95749 | 3/20 | 0.31 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23468504 | 0.98 | KDM5A (0.37) | KDM5AKDM4CHRH3HRH4CHRM2 | |
| SCHEMBL25569661 | 0.87 | CHRM2 (0.39) | HRH3HRH4CHRM2 | |
| SCHEMBL23945777 | 0.86 | SIGMAR1 (0.41) | KDM5AKDM4CHRH3HRH4CHRM2 | |
| SCHEMBL25566723 | 0.85 | CHRM2 (0.37) | HRH3HRH4CHRM2 | |
| SCHEMBL25828466 | 0.83 | KDM4C (0.39) | KDM5AKDM4CHRH3HRH4CHRM2 | |
| SCHEMBL13919919 | 0.82 | — | — | |
| SCHEMBL23696590 | 0.82 | PIK3CD (0.41) | HRH3HRH4CHRM2GGPS1 | |
| SCHEMBL23695951 | 0.82 | PIK3CD (0.41) | HRH3HRH4CHRM2GGPS1 | |
| SCHEMBL23567945 | 0.82 | PIK3CD (0.41) | HRH3HRH4CHRM2GGPS1 | |
| SCHEMBL25881538 | 0.82 | KDM5A (0.35) | KDM5AKDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234936-A1 | COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
| US-20230219945-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234936-A1 | COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | IRAK4, IRAK2, IRAK1 | KDM5A 1197/4885KDM4C 999/4885HRH3 3945/4885 |
| US-20230219945-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | KDM5A 197/4885KDM4C 293/4885HRH3 3631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.